Failures of once-a-week trimethoprim-sulfamethoxazole prophylaxis in children undergoing allogeneic hematopoietic stem cell transplant

Research output: Contribution to journalArticlepeer-review

Abstract

Once-a-week cotrimoxazole is an effective prophylaxis for pneumocystosis during antineoplastic chemotherapy or autologous stem cell transplant. Following allogeneic stem cell transplant, this schedule is at risk of pneumocystosis or neurotoxoplasmosis, as demonstrated by these case reports. Therefore, a 3-times-a-week schedule must be adopted in these patients.

Original languageEnglish
Pages (from-to)e13231
JournalTransplant Infectious Disease
Volume22
Issue number1
DOIs
Publication statusPublished - Feb 2020

Keywords

  • Antifungal Agents/administration & dosage
  • Child
  • Drug Administration Schedule
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Humans
  • Immunocompromised Host
  • Pneumocystis carinii
  • Pneumonia, Pneumocystis/prevention & control
  • Treatment Failure
  • Trimethoprim, Sulfamethoxazole Drug Combination/administration & dosage

Fingerprint Dive into the research topics of 'Failures of once-a-week trimethoprim-sulfamethoxazole prophylaxis in children undergoing allogeneic hematopoietic stem cell transplant'. Together they form a unique fingerprint.

Cite this